TB-500 + Thymosin Alpha-1 Stack: Evidence, Mechanisms, and Protocol

What These Two Peptides Are and Why Practitioners Combine Them

TB-500 and Thymosin Alpha-1 come from the same thymosin superfamily but work through distinct mechanisms. Combining them aims to address tissue repair, immune modulation, and anti-inflammatory signaling simultaneously, areas where the two peptides appear to share at least one common downstream pathway: suppression of NF-kB-driven inflammation.

TB-500: The Tissue-Repair Side of the Stack

TB-500 is a synthetic analog of a 43-amino-acid region of thymosin beta-4 (Tbeta4), the most abundant intracellular actin-sequestering protein in mammalian cells. The active fragment spans residues 17-23 (LKKTETQ) and the flanking Ac-SDKP tetrapeptide. Thymosin beta-4 itself is encoded by the TMSB4X gene and is expressed at high concentrations in platelets, macrophages, and wound-bed cells [1].

The mechanism relies on G-actin binding. By sequestering monomeric actin, Tbeta4 reduces cytoskeletal tension in resting cells and promotes cell migration into wound sites. A 2010 study in the Journal of Cell Science confirmed that Tbeta4 promotes corneal epithelial cell migration through an ILK-dependent pathway [2]. Separately, Tbeta4 upregulates VEGF and stimulates angiogenesis, documented in a cardiac repair model where intraperitoneal Tbeta4 reduced infarct size and improved fractional shortening in mice after coronary ligation [3].

TB-500 also suppresses inflammatory mediators. In a rat model of acute lung injury, thymosin beta-4 reduced TNF-alpha and IL-6 levels by roughly 40% compared with saline controls [4]. That anti-inflammatory action is the mechanistic bridge to Thymosin Alpha-1.

Thymosin Alpha-1: The Immune-Regulation Side of the Stack

Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid peptide derived from prothymosin alpha. It was isolated at the National Cancer Institute in the 1970s. Unlike TB-500, it has a substantial human clinical trial record.

In hepatitis B, a 1996 multicenter trial (N=97) showed thymalfasin 1.6 mg subcutaneously twice weekly for 6 months produced a sustained HBe-antigen loss rate of 40% versus 9% for placebo (P<0.01) [5]. The compound is FDA-designated as an orphan drug for hepatitis B and is licensed as Zadaxin in more than 35 countries. Its mechanism involves TLR-9 agonism, promotion of Th1 polarization, dendritic cell maturation, and upregulation of IL-12 and IFN-gamma [6].

Critically, Thymosin Alpha-1 also modulates NF-kB. A 2012 cell-culture study showed thymalfasin reduced LPS-induced NF-kB nuclear translocation in macrophages by approximately 55%, reducing downstream IL-6 and TNF-alpha secretion [7]. That is the same pro-inflammatory cascade that Tbeta4/TB-500 is documented to suppress.

Mechanistic Overlap: Where the Two Peptides Converge

The two peptides converge at three identifiable nodes, each supported by at least pre-clinical evidence.

Node 1: NF-kB Suppression

NF-kB drives transcription of TNF-alpha, IL-1beta, IL-6, and COX-2. Both thymosin beta-4 and thymalfasin have been shown, in separate experimental systems, to reduce NF-kB activation. A 2014 study in PLOS ONE confirmed Tbeta4 reduces NF-kB p65 phosphorylation in LPS-stimulated microglia [8]. Thymalfasin does the same in macrophages [7]. Stacking both peptides could theoretically produce additive suppression at this node, though no experiment has tested the combination directly.

Node 2: Oxidative Stress Attenuation

Thymosin beta-4 reduces reactive oxygen species (ROS) through Nrf2 pathway activation. A 2019 rodent study showed Tbeta4 pre-treatment cut ROS levels by 38% in hepatic ischemia-reperfusion injury [9]. Thymosin Alpha-1 reduces oxidative damage through a separate mechanism: enhancing superoxide dismutase and catalase activity in aging thymic tissue [10]. Two different antioxidant pathways acting on the same oxidative burden is the theoretical advantage.

Node 3: T-Cell and Macrophage Cross-Talk

TB-500 influences macrophage polarization toward an M2 anti-inflammatory phenotype, promoting wound healing over destruction [11]. Thymosin Alpha-1 drives Th1 T-cell differentiation and NK cell cytotoxicity [6]. These actions are not redundant. The M2 macrophage environment created by Tbeta4 is permissive for the Th1 immune surveillance that Thymosin Alpha-1 supports. In chronic disease states such as post-viral fatigue or non-healing wounds, both arms of this response may be depressed simultaneously, which is the clinical rationale practitioners cite most often.

How Strong Is the Evidence for This Stack?

Honest grading of the evidence matters here. Practitioners and patients deserve a clear picture of what is known versus what is extrapolated.

Evidence Grade for TB-500 Alone

As of January 2025, no peer-reviewed human RCT exists for TB-500 specifically. All human-context extrapolation comes from studies of full-length thymosin beta-4. A Cochrane-level review has not been published for Tbeta4 in any indication. The highest-quality human-relevant data come from cardiac surgery trials using Tbeta4-based gene therapy or protein administration, which remain in early-phase investigation [3]. Animal data are consistent across species (rat, mouse, rabbit) and multiple tissue types (cardiac, corneal, skin, tendon), but cross-species translation carries uncertainty.

Evidence Grade for Thymosin Alpha-1 Alone

Thymosin Alpha-1 has a far stronger evidence base. Beyond the 1996 hepatitis B trial [5], a 2001 Lancet-published pilot RCT (N=40) showed thymalfasin reduced 28-day mortality in sepsis by 29 percentage points compared with placebo [12]. A 2020 RCT in JAMA Internal Medicine (N=361) examined thymalfasin in severe sepsis and found no significant mortality benefit at 28 days overall, but a pre-specified subgroup analysis showed benefit in patients with thymosin Alpha-1 serum levels below the median at baseline [13]. This suggests the peptide may work best when immune exhaustion is present, an important dosing context.

Evidence Grade for the Stack

Zero controlled human trials test this combination. The stack rationale is built from:

• Mechanistic inference drawn from separate studies of each peptide
• Animal data where both peptides were used in models of overlapping pathology (infection plus tissue injury)
• Practitioner case series and patient-reported outcomes in online forums and peptide therapy communities

This does not make the combination irrational. It does mean any claimed benefit rests on an inference ladder, not a clinical trial. Physicians should document this limitation in informed consent.

Dosing Framework for the TB-500 + Thymosin Alpha-1 Stack

No clinical trial has established an optimal combined dose. The framework below is synthesized from RCT doses used for each peptide individually and adjusted for the subcutaneous administration route common to both.

TB-500 Dosing

Standard practitioner-reported protocols use a loading phase of 4 to 8 mg subcutaneously twice weekly for 4 to 6 weeks, followed by a maintenance phase of 2 to 2.5 mg once or twice weekly for 8 to 12 additional weeks. These numbers echo the dose range used in veterinary studies of thymosin beta-4 in equine tendon injuries, where 4 mg per injection was the most common dosing unit [14]. No established human dose-finding study exists.

TB-500 is typically reconstituted in bacteriostatic water at 1 mg/mL and injected subcutaneously into the periumbilical area or the site of injury if superficial.

Thymosin Alpha-1 Dosing

The 1.6 mg subcutaneous dose, given twice weekly, is the best-established human dose from hepatitis B and sepsis trials [5, 12]. Practitioner protocols for off-label use often mirror this: 1.6 mg subcutaneously twice weekly for 8 to 12 weeks. Some practitioners use 1.0 mg twice weekly in lower-risk patients or in combination protocols to reduce potential immune overstimulation.

Injection Timing and Site Rotation

Both peptides are administered subcutaneously. Because they act on partially overlapping pathways, some practitioners administer them at separate sites on the same day rather than on alternating days, theoretically to avoid pharmacokinetic interference. No pharmacokinetic study of combined administration has been published. Site rotation (abdomen, thigh, lateral arm) reduces injection-site induration.

Cycle Length and Washout

A common combined cycle reported in practitioner case series runs 10 to 12 weeks, followed by a 4-to-8-week washout before reassessment. No trial-validated washout period exists. Thymosin Alpha-1's terminal half-life is approximately 2 hours in healthy adults [15], so accumulation is not a concern at standard doses. TB-500's half-life in humans has not been formally published; animal pharmacokinetic data suggest rapid systemic distribution within 1 to 2 hours of injection, with tissue retention lasting several days [1].

Safety Considerations and Contraindications

Thymosin Alpha-1 Safety Profile

In clinical trials, thymalfasin at 1.6 mg twice weekly was well-tolerated. The most common adverse events were mild injection-site reactions (erythema, induration) in approximately 12% of participants, and transient flu-like symptoms in approximately 8% [5]. No serious autoimmune events were reported in the hepatitis B trials. The sepsis trials reported no peptide-attributable serious adverse events distinct from the underlying disease burden [12, 13].

Thymalfasin should be used with caution in patients with autoimmune conditions, as Th1 polarization could theoretically exacerbate diseases such as rheumatoid arthritis or lupus. Pregnancy and lactation are exclusion criteria in all published trials.

TB-500 Safety Profile

Formal human safety data for TB-500 specifically do not exist. Safety inferences come from studies of full-length thymosin beta-4. In a Phase I cardiac trial, intracoronary and intravenous thymosin beta-4 was reported safe at doses up to 1,260 mg total with no dose-limiting toxicities [3]. The subcutaneous peptide fragment doses used in performance-medicine contexts are far below that threshold. The primary theoretical safety concern is pro-angiogenic activity: VEGF upregulation by Tbeta4 could theoretically promote growth of occult tumors. This concern has not been validated in human cancer surveillance studies, but it remains a reason to exclude patients with active malignancy.

Drug Interactions

No formal drug-interaction studies exist for either peptide in combination with small-molecule drugs. Thymosin Alpha-1 may theoretically enhance or complicate the effect of immunosuppressants (cyclosporine, tacrolimus, mycophenolate). Patients on these agents should not use thymalfasin without specialist review. TB-500 does not have documented interactions, but the VEGF-upregulation mechanism suggests caution alongside anti-VEGF biologics such as bevacizumab.

Who May Benefit and Who Should Avoid This Stack

Based on the overlapping mechanistic profiles, the patient types most commonly described in practitioner case series as potential candidates include:

• Adults with post-viral immune fatigue and concurrent musculoskeletal injury, where both immune reconstitution (Thymosin Alpha-1) and tissue repair (TB-500) are desired
• Athletes recovering from tendon or ligament injuries in whom subclinical immune suppression (e.g., from overtraining) is also present
• Patients with chronic wound healing delays secondary to diabetic neuropathy, where both angiogenesis and immune competence are impaired

Patients who should avoid this stack without specialist clearance:

• Active malignancy of any type (pro-angiogenic risk from TB-500)
• Active autoimmune disease on immunosuppressive therapy (Th1 amplification risk from Thymosin Alpha-1)
• Pregnancy or planned pregnancy within the cycle period
• Age <18 years (no pediatric safety data for either compound)
• Organ transplant recipients on anti-rejection therapy

Regulatory and Compounding Status in the United States

Neither TB-500 nor Thymosin Alpha-1 is approved by the FDA for the indications discussed in this article. Thymalfasin carries FDA orphan-drug designation for hepatitis B, but that designation does not authorize off-label compounding or dispensing for immune or tissue-repair applications [16].

The FDA's 2023 and 2024 guidance actions on bulk drug substances for compounding have placed several peptides, including thymosin beta-4, under scrutiny for inclusion on the 503A/503B compounding lists. Practitioners prescribing these compounds through compounding pharmacies must confirm current regulatory status, as it may change. The FDA maintains the current 503B bulks list at its official site [16].

Thymosin Alpha-1 (thymalfasin/Zadaxin) is manufactured by SciClone Pharmaceuticals and is commercially available in more than 35 countries outside the US. In the US, access is through compounding pharmacies under a physician's prescription.

Evidence Gaps and What Research Would Be Needed

The mechanistic case for this stack is cleaner than for most peptide combinations. The gaps that preclude confident clinical recommendations are:

1. No human pharmacokinetic study of TB-500 (the fragment specifically, not full-length Tbeta4).
2. No drug-drug interaction data for the combination.
3. No dose-finding RCT for either peptide in tissue-repair indications in humans.
4. No controlled trial testing the combination, even in animals with a dual-pathology model (infection plus musculoskeletal injury).
5. No long-term safety data beyond 12 months for either compound at the doses used in performance-medicine contexts.

Filling gap 3 alone, a Phase II dose-finding RCT of thymosin beta-4 in tendon repair (something the NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases has acknowledged as a priority area), would materially change the evidence field for TB-500 use.